MyClyns Protects From:

Efficacy Testing

Independent laboratory tests were conducted at BioScience Laboratories, Inc. in Bozeman, MT. The results of those tests are summarized below.

Virus

The solution in MyClyns has shown virucidal activity in in-vitro and clinical (human)
in-vivo testing:

Virus	Study Type	Performance
Human Hepatitis C (BVDV surrogate)	clinical	>99.99% reduction within 30 seconds
Human Immunodeficiency (HIV-1/Mn)	in-vitro	>93.94% reduction within 30 seconds >99.99% reduction within 2.5 minutes
Human Influenza A H1N1 (ATCC #VR-1520)	in-vitro	>99.99% reduction within 30 seconds
Avian Influenza H3N2 A/turkey/OH/31053/04 (AI CAD Program, University of Maryland)	in-vitro	>99.99% reduction within 30 seconds
Herpes Simplex type 1 (HSV-1)	in-vitro	>68.74% reduction within 30 seconds

Bacteria

The solution in MyClyns was tested using the standard OTC clinical (human) monograph test: Healthcare Personnel Handwash (HCPHW) using Serratia marcescens. The solution showed immediate efficacy after one application (>99% bacterial reduction) and met the first reduction criteria for the HCPHW test.

Furthermore, the solution in MyClyns showed >99.99% in-vitro reduction in the following germs in as little as 15 seconds:

Acinetobacter baumannii (ATCC #19003)	Proteus mirabilis (ATCC #7002)
Acinetobacter baumannii (Clinical Isolate: BSLI #061901Ab3)	Proteus mirabilis (Clinical Isolate: BSLI #061901Pm2)
Bacteroides fragilis (ATCC #43858)	Pseudomonas aeruginosa (ATCC #15442)
Bacteroides fragilis (Clinical Isolate: BSLI #061901Bf6)	Pseudomonas aeruginosa (Clinical Isolate: BSLI #072605Pa)
Candida albicans (ATCC #10231)	Pseudomonas aeruginosa (ATCC #27853)
Candida albicans (Clinical Isolate: BSLI #042905Ca)	Pseudomonas aeruginosa (Clinical Isolate: BSLI #061901Pa2)
Clostridium difficile C-diff (ATCC#9689)	Serratia marcescens (ATCC #14756)
Enterobacter aerogenes (ATCC #29007)	Serratia marcescens (Clinical Isolate: BSLI #042905Sm)
Enterobacter aeruginosa (Clinical Isolate: BSLI #042905Ea)	Staphylococcus aureus aureus (ATCC #6538)
Enterococcus faecalis (ATCC #29212)	Staphylococcus aureus MRSA (ATCC #700698)
Enterococcus faecalis (Clinical Isolate: BSLI #061901Efs2)	Staphylococcus aureus VRSA (BSLI #062707NARSAVRSal)
Enterococcus faecium VRE, MDR (ATCC #51559)	Staphylococcus aureus (Clinical Isolate: BSLI #061901Sa1)
Enterococcus faecium (Clinical Isolate: BSLI #061901Efm1)	Staphylococcus aureus (ATCC #29213)
Escherichia coli (ATCC #11229)	Staphylococcus aureus (Clinical Isolate: BSLI #061901Sa2)
Escherichia coli (Clinical Isolate: BSLI #042905Ec1)	Staphylococcus epidermidis (ATCC #12228)
Escherichia coli (Clinical Isolate: BSLI #042905Ec2)	Staphylococcus epidermidis (Clinical Isolate: BSLI #072605Se)
Escherichia coli (ATCC #25922)	Staphylococcus haemolyticus (ATCC #29970)
Haemophilus influenzae (ATCC #8149)	Staphylococcus haemolyticus (Clinical Isolate: BSLI #042905Sha)
Haemophilus influenzae (Clinical Isolate: BSLI #072605Hi)	Staphylococcus hominis (ATCC #27844)
Klebsiella oxytoca MDR (ATCC #15764)	Staphylococcus hominis (Clinical Isolate: BSLI #042905Sho)
Klebsiella oxytoca (Clinical Isolate: BSLI #061901Ko1)	Staphylococcus saprophyticus (ATCC #35552)
Klebsiella pneumoniae subsp. ozaenae (ATCC #29019)	Staphylococcus saprophyticus (Clinical Isolate: BSLI #042905Ss)
Klebsiella pneumoniae (Clinical Isolate: BSLI #061901Kpn2)	Streptococcus pneumoniae (ATCC #33400)
Micrococcus luteus (ATCC #7468)	Streptococcus pneumoniae (Clinical Isolate: BSLI #072605Spn1)
Micrococcus luteus (Clinical Isolate: BSLI #061901M12)	Streptococcus pyogenes (ATCC #19615)
Neisseria gonorrhoreae (ATCC #19424)	Streptococcus pyogenes (Clinical Isolate: BSLI #061901Spy7)
Neisseria meningitidis (ATCC #13102)

VRE = Vancomycin-Resistant Enterococcus
MDR = Multi-Drug Resistant

Click here to view the report summaries of the indepedent laboratory tests that have been performed.

Safety Testing

The solution in MyClyns has been shown to be non-toxic. Below is a summary of toxicity testing that has been performed.

Study	Guidelines	Results
Skin Irritation	ISO 10993-10	Irritation response cateogry: negligible
Ocular Irritation	ISO 10993-10	No positive irritation response
Acute Oral Toxicity	US EPA OPPTS 870.1100	No observable abnormaliites LD50 > 5000 mg/kg
Acute Dermal Toxicity	US EPA OPPTS 870.1200	No observable abnormaliites LD50 > 5000 mg/kg
Acute Inhalation Toxicity	US EPA OPPTS 870.1300	No observable abnormaliites LD50 > 5000 mg/kg
Dermal Sensitization	US EPA OPPTS 870.2600	No sensitizing reaction
Cytotoxiicty (in-vitro)	ISO 10993-5	Non-toxic, grade 0 - in the MEM eloution, and Agar overlay methods
Systemic Toxicity	ISO 10993-5	No indication of systemic toxicity, performed the same as negative control

Click here to read about what is in the solution in MyClyns and how the solution works.